Home / Letter From The Editor / Oct. 19, 2019

Oct. 19, 2019

Oct 19, 2019

It has been over 6 years since the FDA approved Invokana as the first SGLT-2 inhibitor for the treatment of diabetes. When it was introduced there was a cautious optimism based on the tremendous amount of press concerning the fear of urinary tract infections. Usage was slow at first but as the results on glucose control and weight loss became known, prescribers increased their usage.

In December 2016, Jardiance, another SGLT-2 inhibitor, was given the indication to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and cardiovascular disease, and prescribing again increased.


Last month the FDA, after looking at the results of the CREDENCE trial, has given Invokana its most important indication yet. Our advisory board member George Bakris, MD, Professor of Medicine, Director, AHA Comprehensive Hypertension Center, The University of Chicago Medicine, has an inside report on the importance of this new indication.



We can make a difference!


Dave Joffe